Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR3 | P49019 | 3/20 | 0.66 |
| ▸ | MAPT | P10636 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 3/20 | 0.60 |
| ▸ | PKM | P14618 | 2/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | PRSS1 | P07477 | 2/20 | 0.54 |
| ▸ | KAT2B | Q92831 | 3/20 | 0.53 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.52 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10428098 | 1.00 | HCAR3 (0.66) | HCAR3MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL16152114 | 1.00 | HCAR3 (0.66) | HCAR3MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL29306545 | 0.99 | HCAR3 (0.67) | HCAR3MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL14294847 | 0.94 | MAPT (0.69) | HCAR3MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL13168998 | 0.88 | MAPT (0.61) | HCAR3MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL14063303 | 0.88 | HCAR3 (0.65) | HCAR3MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL8147273 | 0.88 | MAPT (0.65) | HCAR3MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL8744502 | 0.87 | MAPT (0.58) | HCAR3MAPTKDM4ELMNAMAPK1 | |
| SCHEMBL17923845 | 0.86 | KAT2B (0.64) | MAPTKDM4EPOLBPKMALDH1A1 | |
| SCHEMBL9098100 | 0.86 | MAPT (0.57) | HCAR3MAPTKDM4ELMNAMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2023-08-15 | — | — | US | disclosed |
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-27 | — | — | US | disclosed |
| US-10703823-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | YALE UNIVERSITY (US) | 2020-07-07 | — | — | US | disclosed |
| US-20190127487-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | YALE UNIVERSITY | 2019-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11725064-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | BRDT, PAICS, KLK3 | HCAR3 2331/4885MAPT 199/4885KDM4E 971/4885 |
| US-20220023428-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | HCAR3 2331/4885MAPT 199/4885KDM4E 971/4885 |
| US-20190127487-A1 | CHIMERIC SMALL MOLECULES FOR THE RECRUITMENT OF ANTIBODIES TO CANCER CELLS | BRDT, PAICS, KLK3 | HCAR3 2331/4885MAPT 199/4885KDM4E 971/4885 |
| US-10703823-B2 | Chimeric small molecules for the recruitment of antibodies to cancer cells | BRDT, PAICS, KLK3 | HCAR3 2331/4885MAPT 199/4885KDM4E 971/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.